Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2/3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5Stomach Neoplasms 2Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasms 1Liver Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Advanced Solid Tumor 1

Interventions

Sorafenib 3lenvatinib 2sintilimab 1pembrolizumab 1halofantrine 1glucose-regulated proteins 1camrelizumab 1Tranexamic Acid 1Thalidomide 1Sunitinib 1Standard of Care 1Saline Solution 1Oxaliplatin 1Nadroparin 1Lidocaine 1Injections 1Immune Checkpoint Inhibitors 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Folfox protocol 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Liver Neoplasms × sintilimab × Clear all
NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown
15 enrolled
Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡